A 15-week, placebo-controlled trial was conducted with 107 pediatric patients with fibromyalgia, ages 12 through 17 years, at LYRICA total daily doses of 75–450 mg per day. The most frequently observed adverse reactions in the clinical trial included dizziness, nausea, headache, weight increased, and fatigue. The overall safety profile in adolescents was similar to that observed in adults with fibromyalgia.
The recommended dose of LYRICA is 75 to 150 mg two times a day, or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Begin dosing at 75 mg two times a day, or 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. The maximum recommended dose of LYRICA is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. We developed a China-localized 12-week simulation model to determine the cost-effectiveness of pregabalin compared to gabapentin in 1000 patients with pNeP and PHN. We utilized a questionnaire of Chinese key opinion leaders to estimate the pre-treatment distribution of pain scores for pNeP and PHN.
- Each point represents a treatment strategy, plotted by its incremental cost (y-axis) and incremental QALYs (x-axis) relative to amitriptyline (reference, shown at the origin).
- Incremental net monetary benefit calculated as (incremental QALYs × willingness-to-pay threshold) − incremental cost, rounded to nearest dollar.
- These results both align with and diverge from previous economic evaluations.
- Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
Interactions with Other Medicines
Pregabalin is a Schedule V controlled substance, which means it has a low potential for abuse. In recent years, however, there is growing concern that pregabalin and its sister drug gabapentin (Neurontin) are being abused and overprescribed. As of August 9, Lyrica still had about 43% of the market for pregabalin, but that’s likely lyrica cost canada to change as patients, doctors and insurers became more aware of the significant difference in price. It didn’t take long for cheaper generic versions of pregabalin to take a bite out of Pfizer’s monopoly of Lyrica, a drug widely used to treat fibromyalgia, diabetic neuropathy and other types of chronic pain. Further, we do not represent that the website will operate without interruption or error, nor do we provide any assurances of the availability or usability of the online shopping services.
8 Weight Gain
A consistent rise in the demand for pregabalin may boost the growth of the market in the future. Other factors such as ongoing research and development initiatives, increase the scope for the approval of new indications for pregabalin. According to the data published by Acta Epileptologica in October 2023, the prevalence of epilepsy in Asia is estimated to be 23 million individuals. Some of the countries with the highest prevalence rates of epilepsy include India and China. The rise in the prevalence of epilepsy also boosts the growth of the market.
We assumed clinical management was similar for PHN and DPN patients. Adverse events were not included in the model because no clinically relevant differences exist between pregabalin and gabapentin within the 12-week time horizon. Rates of therapy discontinuation due to adverse events or lack of efficacy were also assumed to be the same between therapies. We assumed primary care providers clinically managed all patients, and that the likelihood that patients will visit their primary care provider in a given week was a function of average level of pain. The efficacy of additional healthcare services is unknown, particularly if used in conjunction with pregabalin or other pharmacotherapy, thus we did not assign health benefits to them.